



[図1]



[図2]


正常組織で発現する
プロテアーゼによって
活性化されて
非標的細胞に結合

正常組織



病態組織で
活性化した抗体が
正常組織へ移行


病態組織




標的細胞

非標的細胞


[図3]




[図4]




[図5]




[図6]




[図7]




[図8]




[図9A]




[図9B]




[図9C]




[図9D]



[圖10]




[図11]




重鎖の名前	挿入部位	挿入したアミノ酸配列
6R90H1001	TVSSAS [insert] TKGP	LSGRSDNH (配列番号 : 12)
6R90H1002	TVSSAS [insert] TKGP	SGGSGLSGRSDNHGSSGG (配列番号 : 44)
6R90H1003	TV [insert] SSASTKGP	LSGRSDNHG (配列番号 : 45)
6R90H1004	TV [insert] SSASTKGP	SGGSGLSGRSDNHGSSGG (配列番号 : 44)
6R90H1005	TVSSASTK [insert] GP	LSGRSDNHG (配列番号 : 45)
6R90H1006	TVSSASTK [insert] GP	SGGSGLSGRSDNHGSSGG (配列番号 : 44)


[図12-1]




[図12-2]




[図13]




[圖14]




[圖15]




[図16]




[図17]




[図18]



[図19]




[図20]



ゲル	ウェル	サンプル		プロテアーゼ M/M	プロテアーゼ切断部位	MT-SP1に対する反応性
		M/M				
1	1					
	2		VP_IL6R90-G1m/VK1-39P-2-Pk0MT	+	VE [^] IKRTVAAPS	-
	3			-		
	4		VP_IL6R90-G1m/VK1-39P-1-Pk0MT	+	VEI [^] KRTVAAPS	-
	5			-		
	6		VP_IL6R90-G1m/VK1-39P-Pk0MT	+	VEIK [^] RTVAAPS	-
	7			-		
	8		VP_IL6R90-G1m/VK1-39P+2-Pk0MT	+	VEIKRT [^] VAAPS	+
	9			-		
	10		VP_IL6R90-G1m/VK1-39P+3-Pk0MT	+	VEIKRTV [^] AAPS	+
	11			-		
	12		VP_IL6R90-G1m/VK1-39P+4-Pk0MT	+	VEIKRTVA [^] APS	+
	13			-		
	14		VP_IL6R90-G1m/VK1-39P+5-Pk0MT	+	VEIKRTVAA [^] PS	+
	15			-		
2	2		VP_IL6R90-G1m/VK1-39-k0MT	+	VEIKRTVAAPS	-
	3			-		

[図21]



[図22]

PX03-R4_009-G1mISHI01
/VK1-39-k0MT

20	-
+	-

PX03-R2_006-G1mISHI01
/VK1-39-k0MT

20	-
+	-

PX02-R4_017-G1mISHI01
/VK1-39-k0MT

20	-
+	-

PX02-R4_004-G1mISHI01
/VK1-39-k0MT

20	-
+	-

PX02-R2_001-G1mISHI01
/VK1-39-k0MT


20	-
+	-

時間 [h] :


protease :

共通の
分子
マーカー


250 kD
150
100
75
50
37
25
20
15
10




[図23]




[図24]




[図25]




[図26]




[図27]



[図28]




[図29]



[図30A]

6R90EIVHEG4SMP9G4S- 6R90EICHEG4SMP9G4SG1m	Tris	MMP-9	500 nM
			0 nM
6R90EIVHEG4SMP2MP9G4S- 6R90EICHEG4SMP2MP9G4SG1m	Tris	MMP-9	500 nM
			0 nM
6R90EIVHEG4SMP2.2G4S- 6R90EICHEG4SMP2.2G4SG1m	Tris	MMP-2	500 nM
			0 nM
IgG抗体様分子	バッファー	プロテアーゼ	

IgG抗体様分子	バッファー	プロテアーゼ	
6R90EIVHEG4SMP2MP9G4S- 6R90EICHEG4SMP2MP9G4SG1m	Tris	MMP-2	500 nM
			0 nM



[図30B]

6R90EIVHEMP13- 6R90EICHEMP13G1m/VK1-39- k0MT	assay buffer	MMP-13	50 nM 0 nM
IgG抗体様分子	バッファー	プロテアーゼ	

6R90EIVHEMP7.2- 6R90EICHEMP7.2G1m/VK1- 39-k0MT	assay buffer	MMP-7	50 nM 0 nM
6R90EIVHEMP7.1- 6R90EICHEMP7.1G1m/VK1- 39-k0MT			50 nM 0 nM
6R90EIVHEMP2.4- 6R90EICHEMP2.4G1m/VK1- 39-k0MT		MMP-2	50 nM 0 nM
6R90EIVHEMP2.3- 6R90EICHEMP2.3G1m/VK1- 39-k0MT			50 nM 0 nM
6R90EIVHEMP2.2- 6R90EICHEMP2.2G1m/VK1- 39-k0MT		MMP-2	50 nM 0 nM
IgG抗体様分子			
IgG抗体様分子	バッファー	プロテアーゼ	

6R90EIVHEMP2.1- 6R90EICHEMP2.1G1m/VK1- 39-k0MT	assay buffer	MMP-2	50 nM 0 nM
--	-----------------	-------	---------------

IL6R90-G1m/VK1-39-k0MT	assay buffer	MMP-13	50 nM
		MMP-9	
		MMP-7	
		MMP-2	
			0 nM
IgG抗体様分子	バッファー	プロテアーゼ	

